Glenmark Pharma receives USFDA approval for Tacrolimus ointment

Glenmark Pharmaceuticals has received final USFDA for Tacrolimus ointment used for treating atopic dermatitis (eczema). The ointment is a generic version of Protopic ointment, of Leo Pharma AS in the same strength. According to market estimates, Protopic ointment 0.1 per cent a market potential of US$ 109 million per annum.

Company Profile : Glenmark Pharma Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*